An experimental vaccination campaign targeting the Bundibudyo variant of Ebola has begun in Bunia, the capital of Ituri province in the Democratic Republic of Congo (DRC). This area is considered the main center of the outbreak, which has been affecting the eastern part of the country. The campaign started on September 19 and involves nearly 20,000 volunteers, including healthcare workers, emergency responders, and others who may have been exposed to the virus. The goal of the study is to assess how effective the Ervebo vaccine is against the Bundibudyo variant, which was first identified in the DRC four months ago. Professor Steve Ahuka Mundeke, who leads the national response to the Ebola outbreak in the DRC, emphasized the importance of this initiative. He told Mongabay that using the Ervebo vaccine in this research is a key step in gathering scientific data that can help determine how well it protects against the Bundibudyo strain. The DRC received 70,000 doses of the Ervebo vaccine at the beginning of August. This vaccine is currently the only one available for the Zaire strain of Ebola, which is a different variant from the Bundibudyo strain. The Bundibudyo variant of Ebola virus disease does not yet have a specific treatment, making the research even more critical. As of now, more than 3,500 people have died from the disease, with over 7,000 confirmed cases. Researchers and health officials are working to understand the virus better and find ways to combat it effectively. The study in Bunia is part of a broader effort to develop strategies for managing this outbreak and future threats from similar viruses. Health workers and scientists are closely monitoring the participants in the study to track any side effects and assess the vaccine’s effectiveness. The results of this research could have far-reaching implications for public health in the DRC and beyond, as understanding how to protect against the Bundibudyo variant is crucial for controlling the spread of the disease. The campaign represents a significant step in the fight against this challenging strain of Ebola.